pharmaceutical investing Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
New TALVEY® plus DARZALEX FASPRO® data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
IMAAVY® demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia , an autoantibody-driven disease with no FDA-approved therapies
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus disease activity in a Phase 2 study
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
RYBREVANT FASPRO pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
RYBREVANT® plus LAZCLUZE® demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
FDA approves label expansion, cementing TREMFYA® as the only IL?23 inhibitor proven to help stop further joint damage
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave C2 Aero Coronary IVL Catheter
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
SAGA Metals Highlights Radar Project's VTM Enriched Magnetic Concentrate up to 0.9% V2O5 Relative to Panzhihua, China Benchmark of 0.3% V2O5
